A Retrospective Cohort Study on the Risk of Kidney Disease in HIV Positive Individuals Receiving Tenofovir Based Regimens

被引:0
|
作者
Khandelia, Vikash [1 ]
Nama, Umashankar [1 ]
Mahavar, Ashok [1 ]
Rathore, Anjali [1 ]
机构
[1] Govt Med Coll & Hosp, Dept Nephrol, Kota, Rajasthan, India
关键词
Acquired immunodeficiency syndrome; Antiretroviral therapy; Chronic kidney disease; Nephrotoxicity; ANTIRETROVIRAL THERAPY; RENAL DYSFUNCTION; IMPAIRMENT; PREVALENCE;
D O I
10.7860/JCDR/2022/50272.16425
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Exposure to Tenofovir often leads to the development of some irreversible high risk for kidney disease events. In Human Immunodeficiency Virus (HIV) patients, the prolonged treatment with tenofovir use frequently causes mildto-moderate nephrotoxicity. Hence, there is a need to further investigate the efficacy and the adverse effects associated with tenofovir use to combat the decreased morbidity and mortality associated with the declined kidney function. Aim: To investigate the risk of kidney disease associated with tenofovir use. Materials and Methods: A retrospective study was conducted at the tertiary care centre in northern India, from August 2009 to January 2017 and analysed during January to May 2021. The patients with HIV infection who were administered Tenofovir, Lamivudine and Efavirenz (TLE) and Zidovudine, Lamivudine and Nevirapine (ZLN) were included.The patients were divided into two group based on the TLE and ZLN regimen they received. These patients were on a regular follow-up for six months. The data was assessed on the basis of serum creatinine and estimated Glomerular Filtration Rate ( eGFR) (using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation), body weight and Cluster of Differentiation (CD4) count. Results: Out of 703 patients, 364 patients were administered with TLE, while 339 patients received ZLN. In both the groups, the number of patients were between the age 21-40 years was significantly higher, followed by patients between the age 4160 years. The mean weight and CD4 count of the patients in both the groups significantly increased with the progression of time (p<0.001). The creatinine levels at baseline and at 24 months were comparable in both the groups, p>0.05. The mean eGFR level was significantly lowered in TLE group (112.2 mL/ min/ 1.73 m(2)) compared to ZLN group (123.5 mL/ min/1.73m(2)) at 24-months follow-up (p<0.001). Conclusion: Overall results demonstrate that increasing exposure to tenofovir was associated with a higher incidence of CKD. The serum creatinine levels were comparable between the TLE and ZLN group.
引用
收藏
页数:3
相关论文
共 50 条
  • [11] Immunological outcomes of Tenofovir versus Zidovudine-based regimens among people living with HIV/AIDS: a two years retrospective cohort study
    Teshale Ayele
    Habtemu Jarso
    Girma Mamo
    AIDS Research and Therapy, 14
  • [12] Immunological outcomes of Tenofovir versus Zidovudine-based regimens among people living with HIV/AIDS: a two years retrospective cohort study
    Ayele, Teshale
    Jarso, Habtemu
    Mamo, Girma
    AIDS RESEARCH AND THERAPY, 2017, 14
  • [13] Retrospective review of ART regimens in HIV-positive to HIV-positive kidney transplant recipients.
    Barday, Zunaid
    Manning, Kathryn
    Freercks, Robert
    Bertels, Laurie
    Wearne, Nicola
    Muller, Elmi
    TRANSPLANTATION, 2024, 108 (9S)
  • [14] A RETROSPECTIVE COHORT STUDY OF TREATMENT OUTCOMES AMONG HIV POSITIVE INDIVIDUALS WITH EARLY SYPHILIS AT A SINGLE HIV CLINIC
    Hobbs, Emily
    Lawrence, David
    Dean, Gillian
    Creswell, Fiona
    SEXUALLY TRANSMITTED INFECTIONS, 2017, 93 : A16 - A17
  • [15] Mortality risk in the population of HIV-positive individuals in Southern China: A cohort study
    Zheng, Zhigang
    Lin, Jinying
    Lu, ZhenZhen
    Su, Jinming
    Li, Jianjun
    Tan, Guangjie
    Zhou, Chongxing
    Geng, Wenkui
    PLOS ONE, 2019, 14 (02):
  • [16] Infectious disease events in people with HIV receiving kidney transplantation: Analysis of the Swiss HIV Cohort Study and the Swiss Transplant Cohort Study
    Kusejko, Katharina
    Kouyos, Roger D.
    Bernasconi, Enos
    Boggian, Katia
    Braun, Dominique L.
    Calmy, Alexandra
    Cavassini, Matthias
    van Delden, Christian
    Furrer, Hansjakob
    Garzoni, Christian
    Hirsch, Hans H.
    Hirzel, Cedric
    Manuel, Oriol
    Schmid, Patrick
    Khanna, Nina
    Haidar, Fadi
    Bonani, Marco
    Golshayan, Dela
    Dickenmann, Michael
    Sidler, Daniel
    Schnyder, Aurelia
    Mueller, Nicolas J.
    Gunthard, Huldrych F.
    Schreiber, Peter W.
    BMC INFECTIOUS DISEASES, 2024, 24 (01)
  • [17] Predictors of chronic kidney disease and utility of risk prediction scores in HIV-positive individuals
    Woolnough, Emily L.
    Hoy, Jennifer F.
    Cheng, Allen C.
    Walker, Rowan G.
    Chrysostomou, Anastasia
    Woolley, Ian
    Langham, Freya
    Moso, Michael A.
    Weeraratne, Achini
    Trevillyan, Janine M.
    AIDS, 2018, 32 (13) : 1829 - 1835
  • [18] Erratum to: Risk of cardiovascular events among patients with HIV treated with atazanavircontaining regimens: a retrospective cohort study
    Lisa Rosenblatt
    Amanda M. Farr
    Ella T. Nkhoma
    James K. Nelson
    Corey Ritchings
    Stephen S. Johnston
    BMC Infectious Diseases, 16
  • [19] Risk of Preeclampsia in HIV-Positive Pregnant Women Receiving HAART: A Matched Cohort Study
    Boyajian, Talar
    Shah, Prakesh S.
    Murphy, Kellie E.
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY CANADA, 2012, 34 (02) : 136 - 141
  • [20] Dyslipidaemia after switch to tenofovir alafenamide (TAF)-based cART regimens in a cohort of HIV-positive patients: what clinical relevance?
    Gazzola, L.
    Tagliaferri, G.
    De Bona, A.
    Mondatore, D.
    Borsino, C.
    Bini, T.
    Marchetti, G.
    d'Arminio Monforte, A.
    HIV MEDICINE, 2021, 22 (02) : 140 - 145